Sunshine Biopharma, Inc. (SBFM) Income Statement
SBFM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSBFM revenue and net income
Where SBFM's revenue goes
2025Each bar shows an amount and its share of revenue. SBFM kept −16.5% of revenue as net income.
SBFM profit margins
SBFM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +4.1% | +102.9% | +247.7% | +170.9% |
| Gross profit | +11.8% | +91.5% | +204.5% | +142.3% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SBFM quarterly EPS vs estimates
Sunshine Biopharma beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 12, 2026.
SBFM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 | $71,410 | $21,121 | $447,200 | $0 | $0 |
| Cost of revenue | $24.4M | $24.2M | $15.8M | $2.6M | $117,830 | $25,847 | $11,050 | $391,081 | $6,629 | $60,731 |
| Gross profit | $11.9M | $10.7M | $8.3M | $1.7M | $110,596 | $45,563 | $10,071 | $56,119 | −$6,629 | −$60,731 |
| Research & development | $604,308 | $933,902 | $1.9M | $811,858 | $672,209 | $1,728 | $15,204 | $12,800 | $0 | $32,793 |
| Sales, general & admin | $18.5M | $14.9M | $10.8M | $9.5M | $1.9M | $606,643 | $622,729 | $1.2M | $850,561 | $899,584 |
| Total operating expenses | $16.4M | $16.5M | $13.1M | $10.4M | $2.6M | $622,437 | $651,707 | $1.2M | $857,190 | $993,108 |
| Operating income | −$4.5M | −$5.8M | −$4.8M | −$8.7M | −$2.4M | −$576,874 | −$641,636 | −$1.2M | −$857,190 | −$993,108 |
| Interest income | $280,901 | $496,003 | $736,027 | $518,650 | $0 | — | — | — | — | — |
| Interest expense | $0 | $8,774 | $137,308 | $39,412 | $328,818 | $168,105 | $115,901 | $159,420 | $104,829 | $34,732 |
| Income before taxes | −$6.0M | −$5.4M | −$4.1M | −$26.5M | −$12.4M | −$2.8M | −$1.1M | −$2.2M | −$1.0M | −$3.5M |
| Income taxes | $21,609 | −$234,858 | $395,166 | $233,304 | $328,818 | −$1.9M | $383,386 | −$41,528 | $1,288 | $2.5M |
| Net income | −$6.0M | −$5.1M | −$4.5M | −$26.7M | −$12.4M | −$2.8M | −$1.7M | −$2.2M | −$1.0M | −$3.5M |
| EBITDA | −$5.6M | −$5.1M | −$3.8M | −$26.4M | −$12.1M | −$2.6M | −$948,379 | −$2.0M | −$928,780 | −$932,377 |
| EPS (diluted) | −$6.70 | −$2397.40 | −$1206.05 | −$2082.40 | $0.23 | −$0.04 | −$0.08 | −$0.74 | −$0.50 | −$3.10 |
| Gross margin | 32.8% | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% | 47.7% | 12.5% | — | — |
| Operating margin | −12.3% | −16.7% | −19.9% | −199.6% | −1,068.2% | −807.8% | −3,037.9% | −260.9% | — | — |
| Net margin | −16.5% | −14.7% | −18.7% | −615.4% | −5,444.4% | −3,898.7% | −7,860.9% | −482.1% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $8.6M | $9.4M | $9.4M | $8.9M | $9.6M | $8.4M | $9.3M | $7.5M | $7.7M | $6.0M |
| Cost of revenue | $6.8M | $6.0M | $5.5M | $6.3M | $6.0M | $6.2M | $6.5M | $5.6M | $6.9M | $5.2M | $5.1M | $4.0M |
| Gross profit | $2.4M | $2.1M | $3.0M | $3.1M | $3.4M | $2.7M | $3.1M | $2.9M | $2.4M | $2.4M | $2.6M | $2.0M |
| Research & development | $13,222 | $31,724 | $73,501 | $119,298 | $196,232 | $215,277 | $149,272 | $126,362 | $436,235 | $222,033 | $816,328 | $238,012 |
| Sales, general & admin | $3.9M | $8.4M | $4.4M | $3.3M | $4.0M | $3.6M | $4.8M | $3.7M | $3.0M | $3.4M | $2.8M | $2.4M |
| Total operating expenses | $4.0M | $3.5M | $10.2M | $3.6M | $4.4M | $4.0M | $11.6M | $4.0M | $3.6M | $3.7M | $3.8M | $2.8M |
| Operating income | −$1.6M | −$1.4M | −$1.7M | −$531,963 | −$992,846 | −$1.3M | −$2.0M | −$1.1M | −$1.3M | −$1.4M | −$1.2M | −$779,474 |
| Interest income | $48,816 | $48,426 | $57,467 | $75,352 | $72,715 | $75,367 | $99,305 | $108,614 | $143,995 | $144,089 | $187,613 | $207,431 |
| Interest expense | — | — | $0 | $0 | $0 | $8,529 | $8,529 | $49,181 | $245 | $49,181 | $30,110 | $38,527 |
| Income before taxes | −$1.6M | −$1.2M | −$1.7M | −$1.0M | −$2.0M | −$1.2M | −$2.3M | −$982,586 | −$837,991 | −$1.3M | −$1.0M | −$610,530 |
| Income taxes | — | $408,374 | — | −$137,438 | −$209,166 | −$40,161 | — | $215,217 | −$343,691 | $22,353 | $220,267 | $40,952 |
| Net income | −$1.6M | −$1.2M | −$2.1M | −$883,820 | −$1.8M | −$1.2M | −$2.2M | −$1.2M | −$494,300 | −$1.3M | −$1.3M | −$651,482 |
| EBITDA | −$1.5M | −$1.2M | −$1.6M | −$925,095 | −$1.9M | −$1.2M | — | −$917,952 | −$786,870 | −$1.2M | −$957,294 | −$534,793 |
| EPS (diluted) | −$1.15 | −$2.50 | −$0.46 | −$1.90 | −$3.90 | −$0.44 | — | −$9.40 | −$1988.00 | −$400.00 | −$5.00 | −$800.00 |
| Gross margin | 26.2% | 26.0% | 35.3% | 32.6% | 36.4% | 30.7% | 32.2% | 34.0% | 25.3% | 31.2% | 33.4% | 33.4% |
| Operating margin | −17.4% | −17.3% | −19.3% | −5.6% | −10.6% | −14.6% | −21.2% | −13.1% | −13.6% | −17.9% | −15.5% | −13.1% |
| Net margin | −16.9% | −15.4% | −25.0% | −9.4% | −18.8% | −13.3% | −22.5% | −14.2% | −5.3% | −17.0% | −16.3% | −10.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SBFM's financial statements (latest annual report filed April 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SBFM financial results
In fiscal year 2025 (ended December 31, 2025), Sunshine Biopharma reported revenue of $36.3 million, up 4.1% from the year before. It had a net loss of $6.0 million, a net profit margin of −16.5%. Diluted earnings per share came to −$6.70. Over five years revenue grew at an average rate of 247.7% a year.
See the SBFM stock overview for the latest quote and news, or the SBFM chart for price history and technical indicators.
SBFM income statement FAQ
What is Sunshine Biopharma's annual revenue?
Sunshine Biopharma reported total revenue of $36.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 4.1% from $34.9 million the previous year.
Is Sunshine Biopharma profitable?
No. Sunshine Biopharma reported a net loss of $6.0 million in fiscal 2025, a net profit margin of −16.5%; its operating margin was −12.3%.
What is Sunshine Biopharma's gross margin?
Sunshine Biopharma's gross margin was 32.8% in fiscal 2025: for every $100 of revenue, Sunshine Biopharma kept $33 after the direct cost of its products and services.
How much does Sunshine Biopharma spend on research and development?
Sunshine Biopharma spent $0.6 million on research and development in fiscal 2025, 1.7% of revenue.
How fast is Sunshine Biopharma growing?
Revenue grew 247.7% a year on average over the last five fiscal years, from $0.1 million to $36.3 million.
What are Sunshine Biopharma's earnings per share?
Sunshine Biopharma earned $-6.70 per diluted share in fiscal 2025, compared with $-2397.40 a year earlier.
When will Sunshine Biopharma report its next earnings?
Sunshine Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Sunshine Biopharma's fiscal year end?
Sunshine Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 3, 2026.